Lonza unveils new expansion plans at Swiss manufacturing sites, capping off a very busy pandemic
Lonza will expand its drug development in Switzerland yet again with investments in three of its manufacturing sites, the company announced Wednesday, capping off a very busy year for the Euro giant.
The expansion will feature the addition of an aseptic filling line for clinical supply of drug products in Stein, as well as additions to support both clinical and commercial manufacturing at Basel and Visp.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters